A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
In spite of the overall success of treating Wilms tumor, certain patients still have poor
clinical outcomes. The sub-optimal outcomes for patients with anaplastic histology and
recurrent Wilms tumor warrant the identification of new therapeutic agents. The objective of
this trial is to estimate the response rate to two cycles of intravenous topotecan in
children with recurrent Wilms tumor of favorable histology that is refractory to standard
curative therapy.
Phase:
Phase 2
Details
Lead Sponsor:
St. Jude Children's Research Hospital
Collaborators:
GlaxoSmithKline National Institutes of Health (NIH)